Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.